How is adrenocortical cancer being managed in the UK?

Annals of the Royal College of Surgeons of England

Volumn 91, Issue 6, 2009, Pages 489-493

  Aspenall, Sebastian R ^a   ImiSairp, A H ^b   Bliss, R D ^c   Scott Coombes, D ^d   Harklsov, B J ^e   Lenmard, T W J ^f  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^b HOSPITAL RAJA PEREMPUAN ZAINAB II   (Malaysia)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Adrenal cortex neoplasms; Adrenal glands; Adrenocortical carcinoma; Mitotane; Surgery; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIN; MITOTANE;

ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENALECTOMY; ARTICLE; CLINICAL TRIAL; HUMAN; METHODOLOGY; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SURVIVAL; TUMOR RECURRENCE; UNITED KINGDOM;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYTOTOXINS; GREAT BRITAIN; HUMANS; MITOTANE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 70350465157     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588409X432284     Document Type: Article

References (28)

1. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25: 914-926
2. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenal cortical carcinoma in surgically treated patients a retrospective study on 156 cases by the French association of Endocrine Surgeons. Surgery 1992; 112: 972-980
3. Libe R, Gicquel C. Bertagna X, Bertherat J. Molecular genetics of adrenal cortical carcinoma. In: Bertagna X. (ed) Adrenal Cancer. Montrouge, France: John Libbey, 2007; 13-23.
4. Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG et al. Clinical and molecular aspects of adrenocortical tumourigenesis Aust NZ J Surg 2003; 73: 727-738
5. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterisation of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998; 171: 201-204
6. Korobkin M, Lombardi TJ, Aisen AM. Characterisation of adrenal masses with chemical shift and gadolinium enhancement MR imaging. Radiology 1995; 197:411-418
7. 18F-Fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004; 150: 789-792
8. Weiss LM. Comparative histologic study of 43 metastasizing adrenocortical tumours. Am J Surg Pathol 1984; 8: 163-169
9. Van Sloten H. Schaberg A, Smeenk D, Moolenar AJ. Morphological characteristics of benign and malignant adrenocortical tumours. Cancer 1985; 55: 766-773
10. Harrison LE, Gaudin PB, Brennan MF. Pathological features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999; 134: 181-185
11. Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, AN A et al. Immunohistochemica! assessment of Ki-67 in the differential diagnosis of adrenocortical tumours. Urology 2001; 57: 176-182.
12. Tissier F, Louval A, Grabar S, Hagnere AM, Bertherat J, Vacher-Lavenu MC et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinoi 2004; 150: 809-817
13. Doussett B, Gaujoux S, Thillois J-M. Surgical treatment of adrenal cortical carcinoma. In: Bertagna X. (ed) Adrenal Cancer. Montrouge, France: John Libbey, 2007; 71-97.
14. Henry J-F, Sebag F, iacobone M, Mirallie E. Results of laparoscopic adrenalecto-my for large and potentially malignant tumors. World J Surg 2002; 26: 1043-1047
15. Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5: 718-726
16. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2.2bis-(paracholorophenyl)-1,1- dichloroethane (DDD). Arch Pathol 1949; 48: 387.
17. Cai W, Counsel! RE, Djanegara T, Scheingart DE, Sinsheimer JE. Wotring LL. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995; 84: 134-138
18. Allolio B, Hahner S, Weismann D, Fassnacht M, Adrenocortical carcinoma: clinical update. Clin Endocrinol 2004; 60: 273-287
19. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20: 47-53.
20. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 2001; 356: 2415-2418
21. Terzolo M, Angeli A, Fassnacht M. Adjuvant mitotane treatment of adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380
22. http://:www.firm-act.org
23. Fassnacht M, Hahner S, Polat B, Koschker A-C, Kenn W, Flentje M et al. Efficacy of adjuvant radiotherapy of the tumour bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 911 4501-4504
24. Vassilopoulou-Sellin R, Schultz PN. Adrenal cortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92: 1113-1121
25. Icard P, Goudet P, Charpenay C. Adrenal cortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25: 891-897
26. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119: 161-170
27. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001; 136: 543-549
28. Goidwasser F, Bertagna X. Chemotherapy for adrenal cortical cancer. In: Bertagna X. (ed) Adrenal Cancer. Mont rouge, France: John Libbey, 2007; 59-70.